Most patients with PDGFRβ-positive chordoma benefited from imatinib treatment and avoided rapid PD, likely due to tumor necrosis and intra-tumoral subacute bleeding that manifest as liquefaction (36). This evidence concerns the gene PDGFRB and neoplasm.